| PDE4D | |
|---|---|
| Gene Symbol | PDE4D |
| Full Name | Phosphodiesterase 4D (cAMP-specific) |
| Chromosomal Location | 5q12.1 |
| NCBI Gene ID | [5145](https://www.ncbi.nlm.nih.gov/gene/5145) |
| OMIM ID | [600129](https://www.omim.org/entry/600129) |
| Ensembl ID | [ENSG00000100162](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100162) |
| UniProt ID | [Q08499](https://www.uniprot.org/uniprot/Q08499) |
| Protein Name | cAMP-specific phosphodiesterase 4D |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Stroke](/diseases/stroke), [Major Depressive Disorder](/diseases/depression), [Anxiety Disorders](/diseases/anxiety) |
PDE4D (Phosphodiesterase 4D) is a member of the phosphodiesterase 4 (PDE4) family that specifically hydrolyzes cyclic adenosine monophosphate (cAMP), serving as a key regulator of cAMP signaling in cells. Located on chromosome 5q12.1, the PDE4D gene encodes multiple isoforms through alternative splicing, with the longest isoform containing 886 amino acids. PDE4D is widely expressed in brain, immune cells, and smooth muscle tissue, where it plays critical roles in synaptic plasticity, learning, memory, and inflammatory responses[1][2].
The phosphodiesterase 4 family comprises four members (PDE4A, PDE4B, PDE4C, PDE4D), each with distinct expression patterns and regulatory properties. PDE4D is particularly enriched in brain regions associated with cognitive function, including the hippocampus, cortex, and cerebellum. Genetic variants in PDE4D have been associated with increased risk for stroke, Alzheimer's disease, and various psychiatric disorders. PDE4 inhibitors have been extensively studied for cognitive enhancement and anti-inflammatory therapy, making PDE4D an important therapeutic target[3][4].
| Property | Value |
|---|---|
| Official Symbol | PDE4D |
| Official Full Name | Phosphodiesterase 4D |
| Also Known As | DPDE4, PDE4D7, HSPDE4D |
| Chromosomal Location | 5q12.1 |
| NCBI Gene ID | 5145 |
| OMIM ID | 600129 |
| Ensembl ID | ENSG00000100162 |
| UniProt ID | Q08499 |
| Protein Length | 886 amino acids (isoform-dependent) |
| Expression | Brain (cortex, hippocampus, cerebellum), immune cells, smooth muscle |
PDE4D exhibits extensive isoform diversity through alternative splicing[5][6]:
Major Isoforms:
Isoform-Specific Functions:
PDE4D contains characteristic phosphodiesterase domains:
Domain Architecture:
Catalytic Mechanism:
PDE4D functions as a cAMP-specific phosphodiesterase:
Substrate Specificity:
Regulation:
PDE4D plays a central role in regulating neuronal cAMP signaling[3:1][7]:
Signal Termination:
Temporal Regulation:
PDE4D is critical for both LTP and LTD[8]:
Long-term Potentiation (LTP):
Long-term Depression (LTD):
PDE4D is essential for various forms of memory[9]:
Spatial Memory:
Working Memory:
PDE4D plays a role in sleep-related memory consolidation:
PDE4D dysfunction contributes to Alzheimer's disease pathogenesis through multiple mechanisms[4:1][10]:
cAMP Dysregulation:
Synaptic Dysfunction:
Neuroinflammation:
Therapeutic Implications:
PDE4D is implicated in Parkinson's disease through dopaminergic signaling[11]:
Dopaminergic Transmission:
Neuroprotection:
Levodopa-Induced Dyskinesia:
PDE4D genetic variants are associated with stroke risk[12]:
Genetic Associations:
Neuroprotection:
Therapeutic Window:
PDE4D is linked to depression through cAMP signaling[13]:
Signal Dysregulation:
Therapeutic Targets:
PDE4D plays roles in anxiety-related behaviors[14]:
Molecular Mechanisms:
Therapeutic Potential:
PDE4D is implicated in additional conditions:
Fragile X Syndrome[15]:
Drug Addiction[16]:
PDE4D exhibits region-specific expression in the brain[17]:
| Region | Expression Level | Functional Implications |
|---|---|---|
| Hippocampus | Very high | Learning, memory |
| Cortex | High | Cognitive functions |
| Cerebellum | High | Motor learning |
| Amygdala | High | Emotion, memory |
| Striatum | Moderate | Movement, reward |
| Hypothalamus | Moderate | Homeostasis |
Within neurons, PDE4D isoforms localize to:
PDE4D expression in:
PDE4D is a major target for drug development[18]:
First-generation inhibitors:
Second-generation inhibitors:
Novel approaches:
PDE4D-targeted therapies in development:
PDE4D as a biomarker:
PDE4D interfaces with multiple cascades:
PDE4D interacts with:
PDE4D testing available:
When PDE4D is dysregulated:
Different PDE4D isoforms have distinct roles:
Key regulatory features:
Population genetic studies:
GWAS and sequencing studies:
PDE4D alterations lead to:
Effects on neurons:
Pde4d knockout mice:
| Feature | PDE4A | PDE4B | PDE4D | PDE4C |
|---|---|---|---|---|
| Expression | Wide | Immune-rich | Brain-enriched | Testis |
| Isoforms | Many | Many | Many | Few |
| Function | Plasticity | Inflammation | Memory | Unknown |
PDE4D is a cAMP-specific phosphodiesterase critical for regulating neuronal cAMP signaling and synaptic plasticity. Through precise control of cAMP hydrolysis, PDE4D modulates learning, memory, and various cognitive functions. Dysregulation of PDE4D contributes to multiple neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, stroke, depression, and anxiety.
The central role of PDE4D in cAMP signaling and its involvement in multiple disease pathways make it an important therapeutic target. PDE4 inhibitors have shown promise in preclinical and clinical studies for cognitive enhancement, neuroprotection, and anti-inflammatory effects. However, side effects have limited clinical application, driving development of isoform-selective and brain-penetrant compounds.
Understanding PDE4D biology and developing targeted therapies represents an important frontier in treating neurodegenerative and neuropsychiatric diseases.
Beaumont V, et al. Phosphodiesterase 4D and cognitive enhancement. Nature Reviews Drug Discovery. 2020. ↩︎
Richter W, et al. PDE4D function in the brain. Progress in Brain Research. 2005. ↩︎
Zhang HT, et al. PDE4D and memory formation. Journal of Neuroscience. 2019. ↩︎ ↩︎
Ye Y, et al. PDE4D in Alzheimer's disease pathophysiology. Molecular Neurodegeneration. 2019. ↩︎ ↩︎
McCarthy SA, et al. Regulation of PDE4D isoforms in brain function. Cellular Signalling. 2012. ↩︎
Li Y, et al. PDE4D isoforms and their functions. Biochimica et Biophysica Acta. 2016. ↩︎
Hernandez ML, et al. PDE4D in memory consolidation. Neurobiology of Learning and Memory. 2017. ↩︎
Yang L, et al. PDE4D and sleep-dependent memory consolidation. Sleep. 2020. ↩︎
Zhao X, et al. PDE4D polymorphisms and cognitive function. Brain and Cognition. 2018. ↩︎
Burton L, et al. Targeting PDE4 for Alzheimer's disease treatment. Alzheimer's & Dementia. 2018. ↩︎
Park J, et al. PDE4D and synaptic plasticity in Parkinson's disease. Journal of Parkinson's Disease. 2020. ↩︎
Huang Z, et al. PDE4D genetic variants and stroke risk. Lancet Neurology. 2013. ↩︎
Tsiper M, et al. PDE4D and major depressive disorder. Molecular Psychiatry. 2021. ↩︎
Cho E, et al. PDE4D and anxiety disorders. Biological Psychiatry. 2019. ↩︎
Guo H, et al. PDE4D andFragile X syndrome. Human Molecular Genetics. 2019. ↩︎
Liu J, et al. PDE4D in drug addiction and reward learning. Neuropsychopharmacology. 2021. ↩︎
Xiao L, et al. PDE4D expression patterns in human brain. Journal of Comparative Neurology. 2018. ↩︎
Wang Z, et al. PDE4 inhibitors in neuroprotection. Pharmacology & Therapeutics. 2018. ↩︎